Ketamine (2st phase) — Competitive Intelligence Brief

Ketamine (2st phase) (Ketamine (2st phase)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist. Area: Psychiatry, Anesthesia, Pain Management.

marketed NMDA receptor antagonist NMDA receptor Psychiatry, Anesthesia, Pain Management Small molecule

Target snapshot

Ketamine (2st phase) (Ketamine (2st phase)) — Shalvata Mental Health Center. Ketamine is a non-competitive NMDA receptor antagonist that blocks glutamate signaling in the brain, producing rapid-onset dissociative anesthesia and analgesic effects.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ketamine (2st phase) TARGET	Ketamine (2st phase)	Shalvata Mental Health Center	marketed	NMDA receptor antagonist	NMDA receptor
Namenda	MEMANTINE	AbbVie	marketed	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
DXM + Propofol	DXM + Propofol	Seoul National University Hospital	marketed	Dissociative anesthetic combination	NMDA receptor (DXM); GABA-A receptor (propofol)
Intraoperative infusion of esketamine	Intraoperative infusion of esketamine	Nanjing First Hospital, Nanjing Medical University	marketed	NMDA receptor antagonist	NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist class)

1. Turku University Hospital · 3 drugs in this class
2. H. Lundbeck A/S · 2 drugs in this class
3. Ciusss de L'Est de l'Île de Montréal · 2 drugs in this class
4. Shalvata Mental Health Center · 2 drugs in this class
5. New York State Psychiatric Institute · 2 drugs in this class
6. Auris Medical AG · 1 drug in this class
7. AstraZeneca · 1 drug in this class
8. Alameda Health System · 1 drug in this class
9. Centre Hospitalier Universitaire de Nice · 1 drug in this class
10. Asker & Baerum Hospital · 1 drug in this class